Tasigna Improves Outcomes in Newly Diagnosed CML (December 10, 2010)
According to updated results from a Phase III clinical trial, Tasigna® (nilotinib) continues to be more effective than Gleevec® (imatinib) for the initial treatment of adult patients with newly diagnosed... Continue Reading
The U.S. Food and Drug Administration has expanded the approval of Sprycel® (dasatinib) to include the initial treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic... Continue Reading
The U.S. Food and Drug Administration has expanded the approval of Tasigna® (nilotinib) to include the initial treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic... Continue Reading
In the initial treatment of chronic myeloid leukemia (CML), Sprycel® (dasatinib) produces higher response rates than Gleevec® (imatinib). These results were presented at the 2010 annual meeting of the... Continue Reading
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according... Continue Reading
For leukemia patients who undergo allogeneic stem cell transplantation, 10-year results indicate that bone-marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) produce... Continue Reading
In the initial treatment of chronic myeloid leukemia (CML), Tasigna® (nilotinib) appears to produce higher response rates than Gleevec® (imatinib) 400 mg/day. These results were presented at the 2009... Continue Reading
Sprycel® (dasatinib) produces a higher response rate and improves progression-free survival in patients with chronic myeloid leukemia (CML) who have grown resistant to Gleevec® (imatinib), according... Continue Reading
Early Dose Intensity of Gleevec® May Optimize Response for Chronic Phase CML Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML) who receive high doses (600 mg) of Gleevec®... Continue Reading
Advances in the Management of Chronic Myeloid Leukemia: A Report from the 2007 American Society of Hematology (ASH) Meeting IntroductionInitial Treatment of Newly Diagnosed PatientsAre Higher Doses of... Continue Reading